Atlas Trials

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

Clinical trial NCT03630952 · TERMINATED

Trial details

NCT number
NCT03630952
Sponsor
Chengdu Kanghong Biotech Co., Ltd.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration
Start date
2018-12-21
Primary completion
2020-09-10
Enrollment
1157

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.